KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline

Slides:

Advertisements

Similar presentations

Hypertension Diagnosis and Treatment  Based on JNC 7 – published in 2003  Goal: BP

Advertisements

From: Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study Ann Intern Med. 2015;163(5):

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

What should the Systolic BP treatment goal be in patients with CKD?

David Antecol, M.D., FACC, FASH, FRCP(C) Specialist in Clinical Hypertension (American Society of Hypertension) Disclosures: None.

Hypertension JNC VIII Guidelines.

Copyright © 2015 American Medical Association. All rights reserved.

Copyright © 2005 American Medical Association. All rights reserved.

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

Robert C. Stanton, MD American Journal of Kidney Diseases

KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease American Journal of Kidney Diseases

Isolated Systolic Hypertension: An Update After SPRINT

Assessment of Achieved Clinic and Ambulatory Blood Pressure Recordings and Outcomes During Treatment in Hypertensive Patients With CKD: A Multicenter.

KDOQI US Commentary on the 2013 KDIGO Clinical Practice Guideline for Lipid Management in CKD Mark J. Sarnak, MD, MS, Roy Bloom, MD, Paul Muntner, PhD,

Induction of Type 2 Diabetes Mellitus with Antihypertensive Therapy: Is There Any Role of Alpha Adducin, ACE, and IRS-1 Gene? Sumeet Gupta, MPharm, PhD,

Diabetic Kidney Disease: An ACEI (or an ARB) in the Hole

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Improving Transitions in CKD: Failure Mode

Viper venom for diabetic nephropathy

Nat. Rev. Nephrol. doi: /nrneph

Frederic Rahbari-Oskoui, MD, MS American Journal of Kidney Diseases

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

Thinking Beyond New Clinical Guidelines: Update in Hypertension

Management of hypertension in patients with chronic kidney disease

Guideline 1: goals of antihypertensive therapy in CKD

Step Care Therapy for Hypertension in Diabetic Patients

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

A Decade After the KDOQI CKD Guidelines

Volume 79, Issue 12, Pages (June 2011)

Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy Misghina Weldegiorgis, Dick de Zeeuw, Liang Li,

Membranous nephropathy: When and how to treat

Viper venom for diabetic nephropathy

Cardiovascular Disease and CKD: Core Curriculum 2010

Recognition, Pathogenesis, and Treatment of Different Stages of Nephropathy in Patients With Type 2 Diabetes Mellitus George L. Bakris, MD Mayo Clinic.

Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT) Michael V. Rocco,

Systolic Blood Pressure Intervention Trial Goals and Rationale

A New Clinical Prediction Tool for 5-Year Kidney Transplant Outcome

Hypertension management in high risk type II diabetes with CKD: Insights from recent trials with a focus on albuminuria. A case based discussion Matthew.

Audit-based education: a potentially effective program for improving guideline achievement in CKD patients Moniek C.M. de Goeij, Joris I. Rotmans Kidney.

Daniel E. Weiner, MD, MS American Journal of Kidney Diseases

Table of Contents Why Do We Treat Hypertension? Recommendation 5

Salt and Hypertension American Journal of Kidney Diseases

Guidelines for the Older Adult With CKD

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.

Robert C. Stanton, MD American Journal of Kidney Diseases

Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical.

Navdeep Tangri, MD, FRCPC, Daniel E. Weiner, MD, MS

A Decade After the KDOQI CKD Guidelines: A Historical Perspective

A New Era of Renal Denervation Trials for Patients With Hypertension?

Hypertension After Kidney Transplant

GFR Decline and Subsequent Risk of Established Kidney Outcomes: A Meta-analysis of 37 Randomized Controlled Trials Hiddo J. Lambers Heerspink, PhD, Hocine.

Volume 72, Issue 12, Pages (December 2007)

A Decade After the KDOQI CKD Guidelines: A Perspective From Mexico

Beef Tea, Vitality, Creatinine, and the Estimated GFR

Aggressive blood pressure reduction and renin–angiotensin system blockade in chronic kidney disease: time for re-evaluation? Pantelis A. Sarafidis, Luis.

Evidence and Outcomes in CKD

The future of renoprotection: Frustration and promises

Managing Blood Pressure

Daniel E. Weiner, MD, MS, Mark J. Sarnak, MD, MS

Isolated Systolic Hypertension: An Update After SPRINT

Comparative Superiority of ACE Inhibitors Over Angiotensin Receptor Blockers for People With CKD: Does It Matter? Dimitris Mavridis, PhD American Journal.

Volume 73, Issue 5, Pages (March 2008)

Commentary on ‘The DOPPS Practice Monitor for US Dialysis Care: Potential Impact of Recent Guidelines and Regulatory Changes on Management of Mineral.

Juan Jesús Carrero, PhD American Journal of Kidney Diseases

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

An updated general approach for achieving BP goals in people with diabetes. An updated general approach for achieving BP goals in people with diabetes.

A Decade After the KDOQI CKD Guidelines: Impact on the National Kidney Foundation's Kidney Early Evaluation Program (KEEP) Adam Whaley-Connell, DO, MSPH

Clinical Practice Guidelines for Peritoneal Dialysis Adequacy

Sumeska Thavarajah, MD, Daphne H. Knicely, MD, Michael J. Choi, MD

Presentation transcript:

KDOQI US Commentary on the 2017 ACC/AHA Hypertension Guideline Holly J. Kramer, Raymond R. Townsend, Karen Griffin, Joseph T. Flynn, Daniel E. Weiner, Michael V. Rocco, Michael J. Choi, Matthew R. Weir, Tara I. Chang, Rajiv Agarwal, Srinivasan Beddhu American Journal of Kidney Diseases Volume 73, Issue 4, Pages 437-458 (April 2019) DOI: 10.1053/j.ajkd.2019.01.007 Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions

Figure 1 Hazard ratios of kidney outcomes by use of non-thiazide blood pressure–lowering medications versus thiazide diuretic (THZ) medications. Abbreviations: ACE, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; CCB, calcium channel blockers. Data obtained from Reboussin et al.79 American Journal of Kidney Diseases 2019 73, 437-458DOI: (10.1053/j.ajkd.2019.01.007) Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions

Figure 2 Average number of blood pressure (BP) medications needed to achieve a BP goal in clinical trials. Abbreviations: AASK, African American Study of Kidney Disease and Hypertension93; ACCORD, Action to Control Cardiovascular Disease in Diabetes77; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; CKD, chronic kidney disease; IDNT, Irbesartan Diabetic Nephropathy Trial132; MDRD, Modification of Diet in Renal Disease94; RENAAL, Reduction of Endpoints in NIDDM With the Angiotensin II Antagonist Losartan133,134 SBP, systolic blood pressure; SPRINT, Systolic Blood Pressure Intervention Trial3; UKPKDS, United Kingdom Prospective Kidney Disease Study.134 American Journal of Kidney Diseases 2019 73, 437-458DOI: (10.1053/j.ajkd.2019.01.007) Copyright © 2019 National Kidney Foundation, Inc. Terms and Conditions